To align with industry best practices for security and data integrity, Project Data Sphere is requiring users to upgrade their browsers to one that supports encryption protocol TLS 1.2 by December 15, 2017. On that date, Project Data Sphere will disable support of browsers that permit SSL 3.0/TLS 1.0. To prevent any disruption to your access to Project Data Sphere, you must take action. This browser was not recognized and may not be compatible with TLS 1.2 or higher. Please check with the browser's developer to confirm. To view information about this, please visit the FAQ. If you have any further questions, please contact us.
Back to the List
Type(s) of Cancer Breast, Multiple Myeloma, Prostate
A Randomized, Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer
Provider Data DescriptionDataset NCT00869206-D1-Dataset.csv (consort) is one of 10 datasets associated with PubMed ID 28030702. This dataset contains information in the Consort Diagram.
SponsorAlliance for Clinical Trials in Oncology
Data ProviderNational Cancer Institute
Clinical Trials.gov Information
Brief SummaryThis randomized phase III trial studies two different schedules of zoledronic acid to compare how well they work in reducing bone-related complications in patients with breast cancer, prostate cancer, or multiple myeloma that has spread to other places in the body and have bone involvement. Bone-related complications are a major cause of morbidity in patients with metastatic prostate cancer, breast cancer, and multiple myeloma. Zoledronic acid may stop the growth of cancer cells in the bone and may help relieve some of the symptoms caused by bone metastases. It is not yet known whether giving zoledronic acid more or less frequently is more effective in treating patients with metastatic cancer that has spread to the bone.
ConditionsBreast Adenocarcinoma DS Stage I Plasma Cell Myeloma DS Stage II Plasma Cell Myeloma Metastatic Malignant Neoplasm to the Bone Pain Musculoskeletal Complication Urinary Complications
Intervention TypeDrug: zoledronic acid
Drug(s)Drug: zoledronic acid
Blinding MethodNone (Open Label)
Arms InterventionArm I (zoledronic acid every 4 weeks) - Experimental Arm II (zoledronic acid every 12 weeks) - Experimental
Collaborator(s)National Cancer Institute (NCI)
Region(s)United States Puerto Rico
Age Range18 Years and older (Adult, Older Adult)